Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazi n1-yl)-1H-benzimidazol-2-yl]quinolin-2(1 H)-one lactic acid salts

Details for Australian Patent Application No. 2009227003 (hide)

Owner Novartis AG

Inventors Piechon, Philippe; Stowasser, Frank; Polasek, Johanne; Giron, Danielle; Hammerschmidt, Walter; Schreiner, Andreas

Agent Davies Collison Cave

Pub. Number AU-A-2009227003

PCT Pub. Number WO2009/115562

Priority 61/037,746 19.03.08 US

Filing date 18 March 2009

Wipo publication date 24 September 2009

International Classifications

C07D 401/14 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/496 (2006.01) - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

7 October 2010 PCT application entered the National Phase

  PCT publication WO2009/115562 Priority application(s): WO2009/115562

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009227004-Frequency hopping pattern and arrangement for sounding reference signal

2009226988-Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators